Evidence map›Paper›PMID 42008110›Full record

ArticleFEMS microbiology letters2026

Growth-rate dependent response of mycobacteria to relief of inhibition by a bacteriostatic antibiotic.

Priyanka Chauhan, Frank J Bruggeman

Abstract read
In one paragraph

Article in FEMS microbiology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Priyanka ChauhanSystems Biology Lab, A-Life, AIMMS, VU University, De Boelelaan 1087, 1081 HV Amsterdam, The Netherlands.
Frank J BruggemanSystems Biology Lab, A-Life, AIMMS, VU University, De Boelelaan 1087, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0002-0255-4766

Funding

Marie Skłodowska-Curie Actions 713669
6 · The paper itself

Abstract

Pathogenic bacteria generally resume growth upon removal of bacteriostatic antibiotics. However, it is poorly understood how pre-growth conditions influence (i) the lag time before growth resumption and (ii) induction of antibiotics tolerance upon removal of the antibiotics. To study these traits in Mycobacterium smegmatis, we used a stringent-response-inducing bacteriostatic inhibitor, serine hydroxamate (SHX), which mimics a growth-rate-reducing antibiotic. We find that SHX-induced, growth-arrested cells display characteristics typical of persister cells, i.e. low ATP levels, increased antibiotic tolerance, and delayed growth-recovery. Single-cell microscopy shows morphological changes in SHX-treated cells (elongation and polar swelling) and growth resumption upon SHX removal after a lag time. During this lag time, the cells displayed increased antibiotic survival, which remained evident after complete recovery from SHX stress. Varying the SHX dose, exposure time, and pre-exposure growth rate indicated that the duration of the lag phase depends on the SHX exposure time and the prior growth rate, not on the SHX dose. The lag phase could be shortened by over two-fold with the addition of amino acids, pyruvate, or spent medium, indicating that growth inhibition induces a relievable metabolic bottleneck. Our findings align with studies of other (evolutionarily distant) microorganisms, suggesting that mycobacteria may be limited by similar phenotypic trade-offs associated with adaptive responses to sudden growth rate reductions.

Indexed as

Anti-Bacterial AgentsMycobacterium smegmatisSerineHydroxamic AcidsAnti-Bacterial AgentsHydroxamic AcidsSerineantibiotic persistencegrowth ratelag-timemycobacteriaregrowthserine hydroxamate

Identifiers

PMID42008110
PMCPMC13155453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.